首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1524222

非侵入性幽門螺旋桿菌檢測市場- 按測試類型（血清學測試、尿素呼氣測試、糞便/糞便抗原測試）、按方法（實驗室測試、照護端(POC) 測試）、按最終用途（醫院、診斷）實驗室）和預測，2024 - 2032

Non-invasive Helicobacter Pylori Testing Market - By Test Type (Serologic Test, Urea Breath Test, Stool/Fecal Antigen Test), By Method (Laboratory Based Test, Point of Care (POC) Test), By End-Use (Hospital, Diagnostic Labs) & Forecast, 2024 - 2032

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 105 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

隨著幽門螺旋桿菌感染發生率的上升，全球非侵入性幽門螺旋桿菌檢測市場預計 2024 年至 2032 年複合年成長率將超過 7.1%。 NCBI 的一項研究顯示幽門螺旋桿菌感染率為 44.3%。在發展中國家，這一比例為50.8%，高於已開發國家的34.7%。男性感染率為 46.3%，女性感染率為 42.7%。在18歲以上的成年人中，感染率明顯較高，為48.6%，而兒童的感染率較低，為32.6%。

將非侵入性幽門螺旋桿菌檢測方法整合到日常醫療保健實踐中是因為其在無需侵入性操作的情況下診斷幽門螺旋桿菌感染的經過驗證的效率，這與醫療保健提供者提高患者舒適度和降低程序風險的目標一致。

由於非侵入性幽門螺旋桿菌檢測易於使用並被廣泛接受，醫療機構正在將其納入其標準診斷方案中。這一趨勢透過實現及時、準確的診斷來改善患者護理，並增加對非侵入性檢測解決方案的需求，顯示向高效和以患者為中心的醫療保健實踐的更廣泛轉變。

整個非侵入性幽門螺旋桿菌檢測產業根據檢測類型、方法、最終用途和地區進行細分。

到 2032 年，尿素呼氣測試領域將佔據大量非侵入性幽門螺旋桿菌檢測市場佔有率，因為它無需侵入性操作即可有效診斷幽門螺旋桿菌感染。該測試透過測量呼氣樣本中的二氧化碳含量來檢測幽門螺旋桿菌的存在，為內視鏡方法提供了一種方便可靠的替代方案。由於醫療保健提供者優先考慮患者的舒適度和成本效益，尿素呼氣測試以其簡單性和準確性而脫穎而出，推動了其在臨床環境中的採用，並促進了非侵入性測試市場的整體成長。

2024 年至 2032 年間，床邊 POC 測試領域將在非侵入性幽門螺旋桿菌測試市場上實現顯著的複合年成長率。 POC 測試使醫療保健提供者能夠在患者床邊或門診環境中快速獲得結果，有助於及時做出治療決策。這種方法透過快速識別幽門螺旋桿菌感染，特別有利於減少週轉時間並改善患者的治療結果。隨著醫療機構努力尋求高效的診斷解決方案來提高工作流程和患者滿意度，非侵入性 POC 測試的採用不斷成長，突顯了它們在現代臨床實踐中的關鍵作用。

亞太地區非侵入性幽門螺旋桿菌檢測市場規模在預測期內將呈現顯著的複合年成長率。越來越多的醫療保健服務和有關胃腸道健康的意識計劃增加了對有效診斷解決方案的需求。非侵入性檢測因其經濟實惠和患者舒適度而成為該地區的首選，符合微創手術的文化偏好。此外，亞太地區幽門螺旋桿菌感染的高盛行率凸顯了準確且易於使用的檢測方法的迫切性。隨著醫療保健基礎設施的不斷改善和診斷技術的進步，幽門螺旋桿菌非侵入性檢測的採用將會擴大。

產業生態系統分析
產業影響力
- 成長動力
  - 胃和十二指腸疾病的盛行率上升
  - 對有效抗微生物治療的需求不斷增加
  - 實驗室血清學檢測的進展
  - 對即時檢測設備的需求不斷成長
- 產業陷阱與挑戰
  - 監理規定嚴格，幽門螺旋桿菌感染檢出率低
成長潛力分析
監管環境
報銷場景
技術景觀
波特的分析
PESTEL分析
未來市場趨勢

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
血清學檢測
尿素呼氣試驗
糞便/糞便抗原測試

第 6 章：市場估計與預測：依方法，2021 - 2032

主要趨勢
基於實驗室的測試
照護端 (POC) 測試

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診所
診斷實驗室
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott
Biohit Oyj
Bio-Rad Laboratories, Inc.
Cardinal Health
certest Biotech srl
Fisher Scientific
Gulf Coast Scientific
Meridian Bioscience Inc.
Quidel Corporation
Tri-Med

簡介目錄

Product Code: 9134

Global Non-invasive Helicobacter Pylori Testing Market will infer over 7.1% CAGR between 2024 and 2032, ushered by the rising incidences of H. pylori infections. An NCBI study revealed a 44.3% prevalence of H. pylori infection. In developing nations, the rate stands at 50.8%, higher than the 34.7% observed in developed countries. Men exhibit a predominant infection rate of 46.3% compared to 42.7% in women. Among adults >=18 years, the infection rate is significantly higher at 48.6%, while children show a lower rate of 32.6%.

The integration of non-invasive Helicobacter pylori testing methods into routine healthcare practices is directed by their proven efficiency in diagnosing H. pylori infections without invasive procedures, which aligns with healthcare providers goals of improving patient comfort and reducing procedural risks.

As non-invasive helicobacter pylori tests are accessible and widely accepted, healthcare facilities are incorporating them into their standard diagnostic protocols. This trend improves patient care by enabling timely and accurate diagnosis and boosts demand for non-invasive testing solutions, indicating a broader shift towards efficient and patient-centered healthcare practices.

The overall non-invasive helicobacter pylori testing industry is segmented based on test type, method, end-use, and region.

The urea breath test segment will grab a substantial non-invasive helicobacter pylorus testing market share by 2032 due to its effectiveness in diagnosing H. pylori infections without invasive procedures. This test detects the presence of H. pylori bacteria by measuring carbon dioxide levels in breath samples, offering a convenient and reliable alternative to endoscopic methods. As healthcare providers prioritize patient comfort and cost-efficiency, the urea breath test stands out for its simplicity and accuracy, driving its adoption in clinical settings and contributing to the overall growth of the non-invasive testing market.

The Point-of-Care POC test segment will register a noteworthy CAGR in the non-invasive helicobacter pylori testing market between 2024 and 2032. The Point-of-Care POC test segment is increasing because of its rapid and convenient diagnostic capabilities. POC tests enable healthcare providers to obtain quick results at the patients bedside or in outpatient settings, facilitating timely treatment decisions. This approach is particularly beneficial in reducing turnaround times and improving patient outcomes by swiftly identifying H. pylori infections. As healthcare facilities strive for efficient diagnostic solutions that enhance workflow and patient satisfaction, the adoption of non-invasive POC tests continues to grow, underscoring their pivotal role in modern clinical practice.

Asia Pacific non-invasive helicobacter pylori testing market size will exhibit a noteworthy CAGR during the forecast period. Increasing healthcare access and awareness programs about gastrointestinal health have heightened the need for efficient diagnostic solutions. Non-invasive tests are preferred in this region for their affordability and patient comfort, aligning with cultural preferences for minimally invasive procedures. Additionally, the high prevalence of H. pylori infections in Asia Pacific underscores the urgency for accurate and accessible testing methods. As healthcare infrastructure continues to improve and diagnostic technologies advance, the adoption of non-invasive testing for H. pylori will expand.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of gastric and duodenal illnesses
  - 3.2.1.2 Increasing need for effective anti-microbial treatments
  - 3.2.1.3 Advancements in laboratory serological assay
  - 3.2.1.4 Growing demand for point-of-care testing devices
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Strict regulatory regulations and the low detection rate of H. pylori infection
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technological landscape
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Serologic test
5.3 Urea breath test
5.4 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Laboratory based test
6.3 Point of care (POC) test

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Clinics
7.4 Diagnostic laboratories
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa